Ultra-long acting insulin-Fc fusion proteins and methods of use
The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.
1. A fusion protein comprising an insulin polypeptide and an Fc fragment, wherein the insulin polypeptide and the Fc fragment are connected by a peptide linker, wherein the Fc fragment comprises the following sequence:
(SEQ ID NO: 32)
CPKCPAPEMLGGPSVFIFPPKPKDTLLIARTPEVTCVVVDLDPEDPEV
QISWFVDGKQMQTAKTQPREEQFKGTYRVVSVLPIGHQDWLKGKQFTC
KVNNKALPSPIERTISKARGQAHQPSVYVLPPSREELSKNTVSLTCLI
KDFFPPDIDVEWQSNGQQEPESKYRTTPPQLDEDGSYFLYSKLSVDKS
RWQRGDTFICAVMHEALHNHYTQESLSHSPG
and wherein the insulin polypeptide comprises the following sequence:
(SEQ ID NO: 16)
FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSI
CSLYQLENYCN.
2. The fusion protein of claim 1 , comprising domains in the following orientation from N- to C-terminus: (N-terminus)-insulin polypeptide-linker-Fc fragment-(C-terminus).
3. The fusion protein of claim 1 , wherein the insulin polypeptide and the Fc fragment are connected by a peptide linker comprising the following sequence:
GGGGAGGGG (SEQ ID NO: 25).
4. The fusion protein of claim 1 , wherein the fusion protein is a homodimer.
5. The fusion protein of claim 4 , wherein the percentage homodimer of the fusion protein is greater than 90%.
6. The fusion protein of claim 5 , wherein the fusion protein is made using one of HEK293 or CHO cells, and the resulting homodimer titer after purification using Protein A beads or a Protein A column is greater than 40 mg/L.
7. The fusion protein of claim 1 , wherein the insulin receptor IC50 for the fusion protein is less than or equal to 5000 nM.
8. The fusion protein of claim 1 , wherein the serum half-life of the fusion protein in the blood or serum of a target animal upon administration is longer than about 3 days.
9. The fusion protein of claim 8 , wherein the time during which there is a statistically significant decrease in blood glucose level in the target animal relative to a pre-dose level is longer than one of 2 hours, 6 hours, 9 hours, 12 hours, 18 hours, 1 day, 1.5 days, 2 days, 2.5 days, 3 days, 4 days, 5 days, 6 days, 7 days, or longer.
10. The fusion protein of claim 8 , wherein the Normalized Area Over the Curve (NAOC) after a first subcutaneous injection is greater than 150% Fasting Blood Glucose Level (FBGL)·days·kg/mg.
11. The fusion protein of claim 10 , wherein the ratio of the NAOC after the third weekly subcutaneous injection of the fusion protein in a target animal that is a dog to the NAOC after the first subcutaneous injection of the fusion protein in the dog is greater than 0.50.
12. The fusion protein of claim 1 , wherein the fusion protein is formulated as a pharmaceutical composition.
13. The pharmaceutical composition of claim 12 , wherein the fusion protein is present in the pharmaceutical composition at a concentration of about 3 mg/mL or greater.
14. The pharmaceutical composition of claim 13 , wherein the composition is suitable for subcutaneous administration.
15. A method for lowering the blood glucose level of a target animal, the method comprising administering a physiologically effective amount of the fusion protein of claim 1 or a pharmaceutical composition thereof to the target animal.
16. The method of claim 15 , wherein the target animal is a dog diagnosed with diabetes.
17. The method of claim 15 , wherein the fusion protein is administered subcutaneously.
18. The method of claim 15 , wherein the fusion protein is administered daily, twice weekly, or once weekly to the target animal.
19. The method of claim 15 , wherein the fusion protein is administered once weekly to the target animal at a dose between 0.025 and 0.5 mg/kg/week.
20. A fusion protein comprising an inulin polypeptide linked to an Fc fragment, wherein the fusion protein comprises the following sequence:
(SEQ ID NO: 51)
FVNQHLCGSDLVEALALVCGERGFFYTDPTGGGPRRGIVEQCCHSICS
LYQLENYCNGGGGAGGGGCPKCPAPEMLGGPSVFIFPPKPKDTLLIAR
TPEVTCVVVDLDPEDPEVQISWFVDGKQMQTAKTQPREEQFKGTYRVV
SVLPIGHQDWLKGKQFTCKVNNKALPSPIERTISKARGQAHQPSVYVL
PPSREELSKNTVSLTCLIKDFFPPDIDVEWQSNGQQEPESKYRTTPPQ
LDEDGSYFLYSKLSVDKSRWQRGDTFICAVMHEALHNHYTQESLS
HSPG.